UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics (UNCY) up 1.84% today, trading at $3.89. Learn its $107.8 M cap, 27.9 M shares, and dual hyperphosphatemia therapies in CKD and AKI.

Unicycive Therapeutics (UNCY) secures FDA approval for a new kidney‑disease drug, yet faces a six‑month Class II review and market volatility, urging cautious investment.

Unicycive Therapeutics (UNCY) sees a 4.46% rally amid biotech volatility, offering new hyperphosphatemia treatments and a modest $93.6M cap.

Unicycive Therapeutics rises 4.5% amid a broader sector dip, spotlighting its kidney‑disease pipeline while investors weigh fragile prospects and limited capital.